S&P 500   3,395.15 (-2.03%)
DOW   27,646.97 (-2.43%)
QQQ   280.56 (-1.47%)
AAPL   114.51 (-0.46%)
MSFT   210.95 (-2.44%)
FB   280.14 (-1.63%)
GOOGL   1,593.96 (-2.39%)
AMZN   3,214.63 (+0.32%)
TSLA   418.40 (-0.53%)
NVDA   533.23 (-1.91%)
BABA   306.81 (-1.00%)
CGC   18.82 (-4.61%)
GE   7.41 (-2.88%)
MU   52.09 (-1.44%)
AMD   82.36 (+0.49%)
T   27.23 (-2.12%)
F   8.06 (-1.23%)
ACB   4.43 (-5.34%)
GILD   59.54 (-2.06%)
NFLX   483.68 (-0.94%)
NIO   26.47 (-2.54%)
BA   161.59 (-3.45%)
DIS   124.67 (-2.87%)
S&P 500   3,395.15 (-2.03%)
DOW   27,646.97 (-2.43%)
QQQ   280.56 (-1.47%)
AAPL   114.51 (-0.46%)
MSFT   210.95 (-2.44%)
FB   280.14 (-1.63%)
GOOGL   1,593.96 (-2.39%)
AMZN   3,214.63 (+0.32%)
TSLA   418.40 (-0.53%)
NVDA   533.23 (-1.91%)
BABA   306.81 (-1.00%)
CGC   18.82 (-4.61%)
GE   7.41 (-2.88%)
MU   52.09 (-1.44%)
AMD   82.36 (+0.49%)
T   27.23 (-2.12%)
F   8.06 (-1.23%)
ACB   4.43 (-5.34%)
GILD   59.54 (-2.06%)
NFLX   483.68 (-0.94%)
NIO   26.47 (-2.54%)
BA   161.59 (-3.45%)
DIS   124.67 (-2.87%)
S&P 500   3,395.15 (-2.03%)
DOW   27,646.97 (-2.43%)
QQQ   280.56 (-1.47%)
AAPL   114.51 (-0.46%)
MSFT   210.95 (-2.44%)
FB   280.14 (-1.63%)
GOOGL   1,593.96 (-2.39%)
AMZN   3,214.63 (+0.32%)
TSLA   418.40 (-0.53%)
NVDA   533.23 (-1.91%)
BABA   306.81 (-1.00%)
CGC   18.82 (-4.61%)
GE   7.41 (-2.88%)
MU   52.09 (-1.44%)
AMD   82.36 (+0.49%)
T   27.23 (-2.12%)
F   8.06 (-1.23%)
ACB   4.43 (-5.34%)
GILD   59.54 (-2.06%)
NFLX   483.68 (-0.94%)
NIO   26.47 (-2.54%)
BA   161.59 (-3.45%)
DIS   124.67 (-2.87%)
S&P 500   3,395.15 (-2.03%)
DOW   27,646.97 (-2.43%)
QQQ   280.56 (-1.47%)
AAPL   114.51 (-0.46%)
MSFT   210.95 (-2.44%)
FB   280.14 (-1.63%)
GOOGL   1,593.96 (-2.39%)
AMZN   3,214.63 (+0.32%)
TSLA   418.40 (-0.53%)
NVDA   533.23 (-1.91%)
BABA   306.81 (-1.00%)
CGC   18.82 (-4.61%)
GE   7.41 (-2.88%)
MU   52.09 (-1.44%)
AMD   82.36 (+0.49%)
T   27.23 (-2.12%)
F   8.06 (-1.23%)
ACB   4.43 (-5.34%)
GILD   59.54 (-2.06%)
NFLX   483.68 (-0.94%)
NIO   26.47 (-2.54%)
BA   161.59 (-3.45%)
DIS   124.67 (-2.87%)
Log in
OTCMKTS:IMUN

Immune Therapeutics Stock Forecast, Price & News

$0.03
+0.00 (+5.20 %)
(As of 10/23/2020 09:51 PM ET)
Add
Compare
Today's Range
$0.02
Now: $0.03▼
$0.03
50-Day Range
$0.01
MA: $0.02▼
$0.03
52-Week Range
$0.00
Now: $0.03▼
$0.05
Volume5.81 million shs
Average Volume2.02 million shs
Market Capitalization$11,703.50
P/E RatioN/A
Dividend YieldN/A
Beta0.75
Immune Therapeutics, Inc., a late development-stage biopharmaceutical company, focuses on the development, commercialization, and licensing of prescription medications for humans, animals, and pets worldwide. It develops low dose naltrexone and methionine encephalin therapies for human immunodeficiency virus (HIV) infections, autoimmune diseases, immune disorders, or cancer. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in December 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.58 out of 5 stars

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IMUN
Previous Symbol
CUSIPN/A
CIK1559356
Webwww.immunetherapeutics.com
Phone888-613-8802
Employees4

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$110,000.00
Price / Sales0.11
Cash FlowN/A
Price / Cash FlowN/A
Book Value($30.76) per share
Price / Book0.00

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-3,400,000.00
Net MarginsN/A
Return on EquityN/A
Return on Assets-20,660.61%

Miscellaneous

Outstanding Shares445,000
Market Cap$11,703.50
Next Earnings Date11/17/2020 (Estimated)
OptionableNot Optionable
$0.03
+0.00 (+5.20 %)
(As of 10/23/2020 09:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMUN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMUN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Immune Therapeutics (OTCMKTS:IMUN) Frequently Asked Questions

How has Immune Therapeutics' stock price been impacted by Coronavirus?

Immune Therapeutics' stock was trading at $0.0064 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, IMUN stock has increased by 310.9% and is now trading at $0.0263.
View which stocks have been most impacted by COVID-19.

When is Immune Therapeutics' next earnings date?

Immune Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 17th 2020.
View our earnings forecast for Immune Therapeutics.

How were Immune Therapeutics' earnings last quarter?

Immune Therapeutics, Inc. (OTCMKTS:IMUN) announced its earnings results on Friday, August, 14th. The company reported ($1.76) earnings per share (EPS) for the quarter.
View Immune Therapeutics' earnings history.

Are investors shorting Immune Therapeutics?

Immune Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 22,500 shares, an increase of 58.5% from the August 31st total of 14,200 shares. Based on an average daily trading volume, of 355,100 shares, the days-to-cover ratio is presently 0.1 days.
View Immune Therapeutics' Short Interest.

Who are some of Immune Therapeutics' key competitors?

Some companies that are related to Immune Therapeutics include Alseres Pharmaceuticals (ALSE), Acusphere (ACUS), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), Akorn (AKRXQ), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aoxing Pharmaceutical (AOXG), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), Biostar Pharmaceuticals (BSPM), Bohai Pharmaceuticals Group (BOPH), China Botanic Pharmaceutical (CBPI), China Dongsheng International (CDSG) and China Health Industries (CHHE).
View all competitors.

What other stocks do shareholders of Immune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Therapeutics investors own include Northwest Biotherapeutics (NWBO), Alexion Pharmaceuticals (ALXN), AK Steel (AKS), Galiano Gold (AKG), Argitek (AGTK), Agenus (AGEN), Affymetrix (AFFX), Advanced Disposal Services (ADSW), Adamis Pharmaceuticals (ADMP) and Analog Devices (ADI).

Who are Immune Therapeutics' key executives?

Immune Therapeutics' management team includes the following people:
  • Mr. Kevin J. Phelps, Pres, CEO & Director (Age 65, Pay $60k)
  • Mr. Peter Aronstam, CFO & Sec. (Age 68, Pay $60k)
  • Ms. Kelly O'Brien Wilson, Chief Technology Officer
  • Dr. Angus George Dalgleish, Chief Medical Officer and Director of R&D (Age 70)
  • Dr. Joseph M. Fortunak, VP of Global R&D and Chemical Devel. (Age 65)

What is Immune Therapeutics' stock symbol?

Immune Therapeutics trades on the OTCMKTS under the ticker symbol "IMUN."

How do I buy shares of Immune Therapeutics?

Shares of IMUN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immune Therapeutics' stock price today?

One share of IMUN stock can currently be purchased for approximately $0.03.

How big of a company is Immune Therapeutics?

Immune Therapeutics has a market capitalization of $11,703.50 and generates $110,000.00 in revenue each year. Immune Therapeutics employs 4 workers across the globe.

What is Immune Therapeutics' official website?

The official website for Immune Therapeutics is www.immunetherapeutics.com.

How can I contact Immune Therapeutics?

Immune Therapeutics' mailing address is 37 NORTH ORANGE AVENUE SUITE 800M, WINTER PARK FL, 32792. The company can be reached via phone at 888-613-8802.

This page was last updated on 10/26/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.